Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  15: Apr | Mar | Feb | Jan | 14: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
04/16/2015 > 164 patent applications in 113 patent subcategories.

20150105316 - Beta-arrestin effectors and compositions and methods of use thereof: This application describes compounds acting as, for example, β-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases.... Agent:

20150105315 - Polypeptide fragments comprising endonuclease activity and their use: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide... Agent: Centre National De La Recherche Scientifique - Direction De La Politique Industrielle

20150105317 - Glucose-responsive insulin conjugates: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK)... Agent:

20150105318 - Antidiabetic medications: Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.... Agent:

20150105319 - Durable haemostatic scaffold: A method for preparing a haemostatic and adhesive durable scaffold useful for promoting wound healing, and the scaffold so prepared, are provided. The scaffold made of fibrinogen and chitosan is produced by electrospinning techniques, resulting in a material with enhanced endurance, applicable in various medical purposes including surgery, tissue regeneration,... Agent:

20150105320 - Anti-angiogenic treatment of ovarian, breast, and prostate cancer with a combination of antagonists: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer.... Agent:

20150105321 - Coagulation factor vii polypeptides: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.... Agent:

20150105322 - Non-n-glycosylated recombinant human annexin a2: Methods for the expression and purification of non-N-glycosylated human Annexin A2 in yeast, e.g., in Pichia pastoris, purified Annexin A2 produced by those methods, and methods of using the Annexin A2.... Agent:

20150105323 - Collagen compositions and methods of use: The present disclosure provides an engineered collagen composition comprising collagen, wherein the collagen composition is compressed to form a gradient of at least one physical property. Methods of using and of manufacturing the engineered collagen compositions of the present disclosure are also provided.... Agent:

20150105324 - Compositions and methods for treating ptsd and related diseases: The invention described herein pertains to compositions and methods for treating PTSD and related diseases. In particular, the invention described herein pertains to compositions and methods for treating PTSD and related diseases by administering modulators of NMDA NR2-PSD95-nNOS signaling.... Agent:

20150105325 - Recombinant alpha-fetoprotein and compositions thereof: Disclosed are pharmaceutical and synergistic compositions comprising human recombination alpha-fetoprotein expressed in eukaryotic cells for preparation of therapeutic agents for use in oncology, immunotherapy, stem cell therapy and cosmetology and also for the diagnosis of cancer and embryonic pathologies.... Agent:

20150105327 - Compositions and methods for the treatment of vprbp-related cancers: This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods... Agent:

20150105326 - Methyl degron peptide and methods of controlling protein lifespan: The present invention provides an isolated methyl degron peptide and a fusion protein comprising a methyl degron peptide. Also, the present invention provides screening methods for agents affecting protein lifespan and anti-cancer agents. Moreover, the present invention provides methods of controlling protein lifespan, regulating protein expression, and treating cancers by... Agent: Seoul National University (snu) R&d Foundation

20150105328 - Peptoid-peptide hybrids and their use: The invention concerns peptoid-peptide hybrids that may act as protein interaction inhibitors (PPIIs). Another aspect of the invention concerns a method for treating a disorder (e.g., an oncologic disorder) in a human or animal subject, comprising administering an effective amount of a peptoid-peptide hybrid (a peptoid body) of the invention,... Agent:

20150105329 - Methods and pharmaceutical compositions for prevention or treatment of ischemia related organ damage: The present invention relates to methods and compositions for the prevention or treatment of ischemia related organ damage.... Agent:

20150105330 - Active mixtures: e

20150105331 - High-purity cyclopeptide crystal as well as preparation method and use thereof: A high purity cyclopeptide crystal has a structure shown by Formula I. R represents H or a cation forming a pharmaceutically acceptable salt. Also disclosed are a preparation method and a use of the high-purity cyclopeptide crystal.... Agent:

20150105333 - Latent human immunodeficiency virus reactivation: Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-κB activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-κB activity without a second... Agent:

20150105332 - Somatostatin receptor agonist formulations: The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt.... Agent: Camurus Ab

20150105335 - Novel peptide compositions: The present invention provides, among other things, novel peptides and compositions for treating disease.... Agent:

20150105334 - Peptides derived from nkp44: The invention provides specific peptides derived from the cytotoxicity receptor NKp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer.... Agent:

20150105336 - Mucosa-elevating agent: Provided is a mucosa-elevating agent containing 0.1% to 1.0% of a peptide, wherein the peptide is an amphipathic protein having 8 to 200 amino acid residues in which hydrophilic amino acids and hydrophobic amino acids are alternately bonded, and is a self-assembling peptide that exhibits a β structure in an... Agent:

20150105337 - Enterobactin conjugates and uses thereof: The present invention provides novel enterobactin-cargo conjugates, such as compounds of Formula (I), and salts thereof, where X is the cargo and may be an antibiotic, a fluorophore, or biotin. The present invention also provides complexes, compositions, kits, and methods that involve the compounds of Formula (I) and are useful... Agent: Massachusetts Institute Of Technology

20150105338 - Therapeutic compositions comprising phenolic acids for treating conditions related to inappropriate platelet aggregation: The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C1 or C2 and wherein for C2 each carbon is linked by a single or multiple bond... Agent: Provexis Natural Products Limited

20150105339 - Methods for treating resistant diseases using triazole containing macrolides: Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating diseases caused at least in party by resistant bacteria.... Agent:

20150105340 - Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice: An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, nonionic surfactants, humectants, a silicone compound, and water. Also disclosed are... Agent:

20150105444 - Antisense compounds targeting genes associated with fibronectin: The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain... Agent: Isis Pharmaceuticals, Inc.

20150105440 - Antisense modulation of apolipoprotein b expression: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein... Agent: Genzyme Corporation

20150105447 - Fidgetin-like 2 as a target to enhance wound healing: Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2.... Agent: Albert Einstein College Of Medicine Of Yeshiva University

20150105441 - Lim kinasemodulating agents for neurofibromatoses therapy and methods for screening for same: Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a LIMK modulating agent. Also disclosed are compounds newly identified to be inhibitors of... Agent:

20150105448 - Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification: Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the... Agent:

20150105449 - Microrna compounds and methods for modulating mir-122: Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity. The compounds may comprise conjugates to facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a... Agent:

20150105450 - Multi-targeting short interfering rnas: The present invention relates to novel short interfering RNA (siRNA) molecules that are multi-targeted. More specifically, the present invention relates to siRNA molecules that target two or more sequences. In one embodiment, multi-targeting siRNA molecules are designed to incorporate features of siRNA molecules and features of micro-RNA (miRNA) molecules. In... Agent: City Of Hope

20150105446 - Novel activation and transfer cascade for ubiquitin: A novel activating enzyme for ubiquitin, Uba6, is provided. Compositions and methods for inhibiting ubiquitin via the Uba6 pathway are provided. Methods of identifying novel inhibitors of ubiquitination are also provided. Novel RNAi molecules are also provided.... Agent:

20150105442 - Nucleic acid molecule capable of inhibiting expression of periostin gene, method for inhibiting expression of periostin gene, and use of said nucleic acid molecule: Provided is a novel molecule that inhibits the expression of the periostin gene. Also provided are methods of inhibiting the expression of the periostin gene or treating an eye disease using the same.... Agent: Kyushu University National University Corporation

20150105445 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent: Sirna Therapeutics, Inc.

20150105443 - Single-stranded nucleic acid molecule for regulating expression of gene having delivering function: The invention provides a single-stranded nucleic acid capable of inhibiting expression of a target gene having a delivery function. The nucleic acid contains, from the 5′-side to the 3′-side, a 5′-side region (Xc), a linker region (Lx), an inner region (Z), a linker region (Ly) and a 3′-side region (Yc)... Agent:

20150105451 - Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Paraoxonase 1 (PON1), in particular, by targeting natural antisense polynucleotides of Paraoxonase (PON1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the... Agent:

20150105452 - Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions: Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.... Agent:

20150105341 - Substituted nucleosides, nucleotides and analogs thereof: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.... Agent:

20150105342 - In vitro method for predicting disease outcome in stage ii colorectal cancer: The present invention relates to a method for determining the likelihood of disease outcome of a patient diagnosed with microsatellite stable, stage II colorectal cancer. More in particular, the present invention relates to a method for determining the prognosis of a patient diagnosed with microsatellite stable, stage II colorectal cancer... Agent: Universiteit Maastricht

20150105343 - Nucleoside supplementation to promote cellular function, genetic stability and regenerative applications: In various embodiments, a cell culture medium, or a nucleoside cocktail transmission (NCT) medium for the culture of stem cells with improved genetic stability, cellular function and regeneration ability is provided. Illustrative culture media comprise a basal culture medium for stem cells, where the culture medium is supplemented with one... Agent:

20150105344 - Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same: The invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation.... Agent:

20150105345 - Uses of antagonists of hyaluronan signaling: Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided... Agent: The Universtiy Of North Carolina At Chapel Hill

20150105346 - Dextran-based polymer tissue adhesive for medical use: A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive... Agent: Actamax Surgical Materials, LLC

20150105347 - Shape-changing droplet: Shape-changing droplets, compositions comprising shape-changing droplets, methods of depositing benefit agents onto substrates using shape-changing droplets, and methods of making shape-changing droplets.... Agent:

20150105348 - Compositions and methods for reducing lactate levels: The present disclosure provides methods of reducing levels of lactate in a fluid or tissue in an individual. The present disclosure provides pharmaceutical compositions suitable for use in the methods.... Agent:

20150105349 - (r)-(-)-1,2-propanediol compositions and methods: Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an... Agent:

20150105350 - Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections: The use of the hemifumarate form of {9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine} (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition, the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and elvitegravir, and the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and darunavir, are disclosed.... Agent: Gilead Sciences, Inc.

20150105351 - Compounds and methods for treating hiv infections: The present invention is directed to novel nanomolar and picomolar inhibitors of HIV reverse transcriptase, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV-1 and HIV-2 and/or secondary disease states and/or conditions which occur as a consequence of HIV... Agent:

20150105352 - Combination of an hmg-coa reductase inhibitor and a farnesyl-pyrophosphatase synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological... Agent:

20150105353 - Stable composition for controlling biological growth and method for using same in oil field applications: A stabilized composition is disclosed which contains at least two biocides, particularly at least two non-oxidizing biocides. In one embodiment, the composition contains a phosphonium sulfate compound combined with a dialkyl dimethyl quaternary amine compound. In order to stabilize the composition, an alkyl trimethyl ammonium compound is added to the... Agent:

20150105354 - Heterocyclic aspartyl protease inhibitors: s

20150105355 - 4-dedimethylamino tetracycline compounds: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux... Agent: Paratek Pharmaceuticals, Inc.

20150105356 - Materials and methods for treatment and diagnosis of disorders associated with oxidative stress: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema.... Agent: Therapeutic Research LLC

20150105358 - Combinations of histone deacetylase inhibitors and immunomodulatory drugs: The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of multiple myeloma in a subject in need thereof. The combinations may, optionally, further comprise an anti-inflammatory agent, such as dexamethasone. Also provided herein are methods for treating multiple myeloma in a subject in... Agent: Acetylon Pharmaceuticals, Inc.

20150105357 - Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method thereof: An oily formulation of fulvestrant or derivatives thereof and a method for producing the same. The oily formulation comprises: fulvestrant or derivatives thereof in an amount of 10 mg/ml to 170 mg/ml; a lactate compound in an amount of 5 to 80% of the total weight of the formulation; a... Agent:

20150105359 - Pharmaceutical composition for emergency contraception: The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions.... Agent:

20150105360 - Therapeutic compositions and method: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present... Agent:

20150105361 - Methods for treating polycystic kidney disease and polycystic liver disease: The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant... Agent: Yale University

20150105362 - Synthesis of estetrol via estrone derived steroids: A process is provided for the making of estetrol starting from a 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is an C1-C5 alkyl group, preferably a methyl group, or a C7-C12 benzylic group, preferably a benzyl group. This process is particularly suitable to industry.... Agent: Pantarhei Bioscience B.v.

20150105363 - Methods and formulations for treating scars and beta-catenin-mediated disorders: A topical drug composition for treating a β-catenin-mediated disorder in a mammal is provided comprising a Nefopam compound selected from Nefopam, or a functionally equivalent analogue, prodrug, salt or solvate thereof.... Agent:

20150105365 - Heteroaryl linked quinolinyl modulators of rorgammat: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one... Agent: Janssen Pharmaceutica Nv

20150105364 - Nmda receptor modulators and uses thereof: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of... Agent: Northwestern University

20150105369 - Alkyl linked quinolinyl modulators of roryt: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one... Agent:

20150105371 - Co-crystals and salts of ccr3-inhibitors: e

20150105366 - Methylene linked quinolinyl modulators of roryt: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one... Agent: Janssen Pharmaceutica Nv

20150105368 - Pyrazolyl quinoxaline kinase inhibitors: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.... Agent: Astex Therapeutics Ltd

20150105367 - Raf inhibitor compounds: This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.... Agent:

20150105370 - Selectively substituted quinoline compounds: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.... Agent:

20150105375 - Methods for treating pulmonary emphysema using substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c: b

20150105373 - Nitrogenated heterocyclic compound:

20150105376 - Quinolinone carboxamide inhibitors of endothelial lipase:

20150105372 - Secondary alcohol quinolinyl modulators of roryt: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one... Agent: Janssen Pharmaceutica Nv

20150105374 - Substituted annellated pyrimidines and use thereof: The present application relates to novel substituted annellated pyrimidines, methods for production thereof, use thereof alone or in combinations for treating and/or preventing diseases and use thereof for the production of medicinal products for treating and/or preventing diseases, in particular for treating and/or preventing cardiovascular diseases.... Agent:

20150105377 - Methods and compositions for raf kinase mediated diseases: The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.... Agent:

20150105378 - Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors: e

20150105379 - Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity:

20150105380 - Methods and uses of compounds for treating disease:

20150105381 - Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors: The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level... Agent:

20150105383 - Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma: The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically... Agent: Acetylon Pharmaceuticals, Inc.

20150105382 - Pyrimidine substituted purine compounds as kinase (s) inhibitors: e

20150105385 - Heterocyclic compounds and uses thereof: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.... Agent:

20150105384 - Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell,... Agent: Acetylon Pharmaceuticals, Inc.

20150105386 - 4-(4-pyridinyl)-benzamides and their use as rock activity modulators: The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R2 are, independently of each other, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy or C1-C8-haloalkoxy;... Agent:

20150105387 - Substituted diketopiperazines and their use as oxytocin antagonists: e

20150105389 - 3,5-diaminopyrazole kinase inhibitors: Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.... Agent:

20150105388 - Carboxamide-substituted heteroaryl-pyrazoles and the use thereof: This invention relates to new carboxamide-substituted heteroaryl-pyrazoles, method for their production, their use for the treatment and/or prophylaxis of diseases, as well as their use for the production of pharmaceutical agents for the treatment and/or prophylaxis of diseases, in particular retroviral diseases, in humans and/or animals.... Agent: Aicuris Gmbh & Co. Kg

20150105390 - Compounds and compositions as protein kinase inhibitors: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion... Agent: Irm LLC, A Delaware Limited Liability Company

20150105392 - Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and... Agent: Theravance Biopharma R&d Ip, LLC

20150105391 - Small molecule modifiers of the hec1-nek2 interaction in g2/m: In Formula 1, Z is —CO—, —SO—, or —SO2—; Ar is phenyl, heteroaryl, or heterocycloalkyl; Het is heteroaryl; R is R″, X, or NR1R2; R′ is R3, or OR3; R″ is R4, or OR4; R1 and R2 are each independently H, alkyl, or acyl; R3 is H, heteroaryl, or alkyl;... Agent:

20150105393 - Amide derivatives as ttx-s blockers: The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these... Agent:

20150105395 - Activators of human pyruvate kinase: Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R1 to R16 are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for... Agent:

20150105396 - Chemical compounds: s

20150105394 - Cyclolic hydrazine derivatives as hiv attachment inhibitors: Compounds of Formula I are provided, including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: wherein Z is selected from the group consisting of: which are useful as HIV attachment inhibitors.... Agent:

20150105397 - Piperazine derivatives and the use thereof as medicament: m

20150105398 - Isoxazoline-substituted benzamide compound and pesticide: wherein X1 is selected from the group consisting of a halogen atom, —SF5, C1-C6haloalkyl, hydroxy C1-C6haloalkyl, C1-C6alkoxy C1-C6haloalkyl, C3-C8halocycloalkyl, C1-C6 haloalkoxy C1-C3haloalkoxy C1-C3haloalkoxy, C1-C6haloalkylthio, C1-C6haloalkylsulfinyl and C1-C6haloalkylsulfonyl; X3 is selected from the group consisting of a hydrogen atom, halogen atom, cyano, nitro, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy and C1-C6 alkylthio; X4 is... Agent:

20150105399 - 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs: Disclosed in the present invention is a 3-cyanoanilinoalkylarylpiperazine derivatives and use thereof in preparing drugs; the 3-cyanoanilinoalkylarylpiperazine derivatives disclosed by the present invention has very useful pharmaceutical properties and good tolerance, especially the use as novel analgesic drugs, novel antidepressants, and novel analgesic and antidepressive drugs. This class of compounds... Agent:

20150105400 - Therapeutic agent for cerebral infarction: The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since... Agent: Mitsubishi Tanabe Pharma Corporation

20150105401 - Mlk inhibitors and methods of use: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition.... Agent: The University Of Rochester

20150105402 - Trazodone and trazodone hydrochloride in purified form: A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of... Agent: Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

20150105403 - Estrogen receptor modulators and uses thereof: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon... Agent:

20150105405 - N-substituted hetero-bicyclic compounds and derivatives for combating animal pests ii: s

20150105404 - Phenyl linked quinolinyl modulators of roryt: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one... Agent: Janssen Pharmaceutica Nv

20150105406 - Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent: The present patent application relates to a pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent. Particularly, the present patent application provides a pharmaceutical composition comprising a thienopyrimidinedione compound as a TRPA1 antagonist and an analgesic agent; and use of such composition for treating pain in a subject.... Agent:

20150105407 - Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof: and pharmaceutically acceptable salts, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds and pharmaceutical compositions for treating tumor cells and inhibiting mitosis... Agent:

20150105408 - Crystalline pl3 kinase inhibitors: There is provided inter alia 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide in the form of a solid crystalline hydrate and in solid crystalline anhydrous form. There are also provided dry powder pharmaceutical compositions for inhalation containing such solid crystalline forms.... Agent:

20150105409 - Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma: The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a BTK inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically... Agent: Acetylon Pharmaceticals, Inc.

20150105410 - Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.... Agent:

20150105411 - Biomarkers of response to nae inhibitors: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.... Agent: Millennium Pharmaceuticals, Inc.

20150105412 - Combination therapy with mdm2 and efgr inhibitors: Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent... Agent:

20150105414 - Hair growth and/or regrowth compositions: The present disclosure relates to compositions containing certain pyrimidine compounds such as minoxidil and/or certain pyrimidine sulfate (inner salt) compounds such as minoxidil sulfate and especially compositions containing pyrimidine compounds in combination with an admixtures comprising at least one antioxidant, at least one organic acid and a select fatty acid... Agent:

20150105413 - Therapeutic compounds: The present invention relates to compounds of formula (I): wherein R1 is NH2 or NHMe; R2 is halo; and one of R3 or R4 is hydrogen and the other is selected from —SO2NH2, —SO2NHMe or —SO2NMe2, —SO2NHEt, or —SO2NEt2; or a pharmaceutically acceptable salt or solvate thereof. The compounds of... Agent: Changzhou Le Sun Pharmaceuticals Limited

20150105415 - Tricyclic compound and use thereof: (wherein, all the symbols have the same meaning as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially... Agent: Ono Pharmaceutical Co., Ltd.

20150105416 - Treating postoperative nausea and vomiting: Methods, compositions, systems, and packaging are disclosed for reducing postoperative nausea and/or vomiting (PONV) in a human patient in need of general anesthesia for surgery. Such methods may include scheduling a surgery for the human patient, and administering to the patient one or more series of prescribed medicines for at... Agent:

20150105417 - Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway: The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for... Agent:

20150105418 - Substituted hydroxamic acids and uses thereof: wherein R1a, R1b, R1c, R1d, R2a, R2b, X1, X2, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or... Agent: Millennium Pharmaceuticals, Inc.

20150105419 - Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c}pyridines: Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed. The method involves exposing the cells to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines of formula (I)... Agent:

20150105420 - [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors: The present invention relates to novel [1,2,4]triazolopyridine compounds with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.... Agent:

20150105421 - Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with... Agent:

20150105422 - Salts and solvates of a tetrahydroisoquinoline derivative: (S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described.... Agent: Spinifex Pharmaceuticals Pty Ltd

20150105423 - Use of cdk9 inhibitors to reduce cartilage degradation: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment... Agent:

20150105424 - Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain: Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.... Agent: Acelrx Pharmaceuticals, Inc.

20150105425 - Kits and methods for treating post traumatic stress disorder (ptsd) and hot flashes: The present invention is directed to kits and methods for the treatment of a patient suffering from post-traumatic stress disorder (PTSD) and/or hot flashes by an administration of a mixture produced by a combination of a long acting local anesthetic combined with clonidine. The combination of the two pharmaceuticals produces... Agent:

20150105426 - Topical emulsions based on mixtures of local eutectic anaesthetics and fatty acids as analgesics, antalgics, or as sexual retardants: The invention relates to novel formulations for topical local anaesthesia and for the use thereof as analgesics, antalgics, or as sexual retardants.... Agent: Universite Paris Descartes

20150105428 - Compositions and methods for modulating circadian synchronization: The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases... Agent:

20150105427 - Pest control agent: e

20150105429 - Benzyl sulfonamide derivatives as rorc modulators:

20150105430 - Methods of treating or preventing neuropathic pain: A method treats or prevents neuropathic pain with a synergistically-enhanced analgesic effect at a dose at which a calcium channel α2δ ligand does not produce any side effects as well as which agent does not produce any new side effects on the central nervous system. The therapeutic agent or a... Agent:

20150105431 - Nicotine lozenge composition: The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form.... Agent:

20150105432 - 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with... Agent: Otsuka Pharmaceutical Co., Ltd.

20150105433 - Treating viral infections having viral rnas translated by a non-ires mediated mechanism: Provided herein are methods for preventing or treating a viral infection in a subject, wherein the viral infection is mediated by a virus comprising one or more viral RNA molecules translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism. The methods comprise administering to a subject an agent... Agent:

20150105434 - Biomarkers for iap inhibitor therapy: A method of selecting a subject having cancer for treatment with an IAP inhibitor.... Agent:

20150105435 - Compounds and methods for regulating integrins: A method of treating inflammation, by administering an effective amount of a β2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a β2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed... Agent:

20150105436 - Methods and assays for detecting and treating hypoglycemia: Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for heating hypoglycemia. The methods are useful for treating diabetes melititus and screening drug candidates for potential efficacy.... Agent:

20150105437 - Process for the preparation of random radical copolymers, and active substance compositions obtainable therefrom: being dissolved either (i) in a solvent mixture comprising water and a water-soluble organic solvent with a boiling point of less than 140° C. or (ii) being dissolved in one or more pure alcohols by heating, and being polymerized in solution, where the polymer formed remains in solution. The copolymers... Agent:

20150105438 - Substituted isoindoline-1,3-dione derivatives: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions... Agent: Concert Pharmaceuticals, Inc.

20150105439 - Treatment of drug-resistant cancer with 2-aryl-2-(3-indolyl) acetohydroxamates: R1, R2, R3 and R4 are optionally substituted and are hydrogen, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C1-10 alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitroalkyl, cyanoalkyl, acetamidoalkyl, acyloxyalkyl, hydroxyl, alkoxy, acetoxy, amino, alkylamino, acetamido.... Agent:

20150105453 - Methods for making and using novel semi-synthetic small molecules for the treatment parasitic disease: Small molecule therapeutics for the treatment of parasitic diseases, in particular, semi-synthetic derivatives of the fugally-derived natural product merulin A for the treatment of African Sleeping Sickness.... Agent: The Regents Of The University Of California

20150105454 - Sparstolonin b based pharmaceutical agent for neuroblastoma treatment: Use of sparstolonin B in inhibition of growth and/or viability of human neuroblastoma cells is described. The sparstolonin B can be naturally derived from the Chinese herb Sparganium stoloniferum or can be synthetic. The sparstolonin B is shown to be effective both in vitro and in vivo in inhibition of... Agent:

20150105455 - Winterized crude cannabis extracts and methods of preparation and use: The present technology relates to liquid compositions for use in a personal vaporizer. More particularly, the present technology relates to liquid compositions comprising winterized Cannabis extract, and to methods of administering vaporized winterized Cannabis extract to a subject by inhalation.... Agent:

20150105456 - Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.... Agent:

20150105458 - Line leaf inula flower lactone a and methods for preparing and using the same for treating multiple sclerosis: Line leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically... Agent: Shanxi Zhendong Pilot Biological Science And Technology Co., Ltd.

20150105457 - Line leaf inula flower lactone a and methods for preparing and using the same for treating myocarditis: The compound shows positive therapeutic activity against Coxsackie virus and significant dose dependent correlation. The line leaf inula flower lactone A prevents disease in mouse models of experimental autoimmune myocarditis and onset of the process by intraperitoneal injection of a dose of 20 mg/kg/d. When increased to 100 mg/kg/d, the... Agent: Shanxi Zhendong Pilot Biological Science And Technology Co., Ltd.

20150105460 - Labdane diterpenoid compounds, semen biotae extract, and preparation method and use thereof: Provided in the present invention are various labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. Also provided in the present invention is a semen biotae extract comprising one or more labdane diterpenoid compounds and derivatives thereof for use... Agent:

20150105459 - Lichesterinic acid and the derivatives of same as pigmentation inhibitors: The invention relates to the cosmetic use of a compound chosen from the compounds of formula (A) and the salts of same as an agent for depigmenting the skin and/or keratinous appendages.... Agent:

20150105461 - Metal delivery agents and therapeutic uses of the same: The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated... Agent: The University Of Melbourne

20150105462 - Compositions and methods for topical delivery of prostaglandins to subcutaneous fat: Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a... Agent: Topokine Therapeutics, Inc.

20150105464 - 4-oxo-2-pentenoic acid and brain health: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of brain health, for example brain protection, maintenance of cognitive function, prevention of cognitive decline and prevention of cognitive disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic... Agent: Nestec S.a.

20150105463 - Sodium pyruvate oral rehydration salt composition for treating hypovolemia or hyponatration associated with hypohydration: Disclosed in the present invention is a sodium pyruvate oral rehydration salt composition for treating hypovolemia or hyponatration associated with hypohydration, said composition containing the following components: (i) 2.0-6.0 parts by weight of sodium pyruvate; (ii) 1.5-17.0 parts by weight of sodium chloride; (iii) 0-2.0 parts by weight of potassium... Agent:

20150105465 - Antiseptic compositions, methods and systems: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses... Agent:

20150105467 - Formulations of low dose diclofenac and beta-cyclodextrin: The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in... Agent: Javelin Pharmaceuticals, Inc.

20150105466 - Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products: The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% of 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions.... Agent:

20150105469 - Methods of treating urea cycle disorders: The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's... Agent:

20150105468 - Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use: The present invention relates to a pharmaceutical composition of ibuprofen and tramadol for ophthalmic use. Said composition is effective and safe for the treatment of ocular inflammation and/or pain associated to different diseases or pathological states which affect the eye area In particular, the ophthalmic composition of the invention is... Agent:

20150105470 - Process for obtaining a modafinil-based pharmaceutical composition, resulting pharmaceutical composition and use thereof: The present invention relates to a novel method for obtaining a pharmaceutical composition based on modafinil. This method consists of solubilizing S modafinil in a fluid in the supercritical state and then after expansion of said fluid, recovering S modafinil by causing it to be absorbed at the surface by... Agent:

20150105471 - Paracetamol for parenteral administration: The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has an electrical conductivity of not more than 200 μS cm−1. The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has... Agent: Fresenius Kabi Deutschland Gmbh

20150105472 - Antimicrobial composition: The invention relates to an antimicrobial composition comprising chlorhexidine and pentane-1,5-diol. Such a composition may be used to combat microorganisms.... Agent:

20150105473 - An antibacterial composition with low amounts of surfactant and antibacterial actives: An antibacterial composition includes at least one surfactant that is less than 6.0 weight percent of the composition and at least one antibacterial active that is less than 0.2 weight percent of the composition. The composition also has a pH between 6.0 and 6.5. The composition also exhibits an efficacy... Agent: The Dial Corporation

20150105474 - Isoamyl nitrite formulations: The present invention is directed at isoamyl nitrite formulations suitable for use in medicinal applications. The formulations include a composition of isoamyl nitrite in combination with an epoxidized vegetable oil, identified as stabilized isoamyl nitrite. The isoamyl nitrite may also be combined with petrolatum. Methods of treatment of the formulations... Agent:

20150105475 - Point of use generation of amyl nitrite: The present disclosure relates to devices and methods for the preparation of amyl nitrite formulations at a point of use location from relatively shelf-stable reagents employing acidic cationic exchange resins.... Agent:

20150105476 - O/w type cosmetic composition with improved dosage form stability: The present invention relates to an O/W type cosmetic composition with improved formulation stability, and more particularly, to an O/W type cosmetic composition comprising a branched polymer having a lipophilic alkyl side chain and an anionic surfactant, as active ingredients for improving formulation stability.... Agent:

20150105477 - Gel-like composition: e

20150105478 - Polyelectrolyte complexes for biocide enhancement: The invention relates to a composition comprising a polyelectrolyte complex of a polyanion and a polycation, and comprising at least one biocide. A preferred composition comprises lignosulfonate and chitosan, preferably in relative a amount of from 1:2 to 60:1 (w/w). The invention further relates to methods for generating a composition... Agent:

  
04/09/2015 > 122 patent applications in 91 patent subcategories.

20150099690 - Compositions and methods for the delivery of molecules into live cells: The present disclosure provides methods and compositions related to the cytosolic delivery of proteins and cell-impermeable small molecules into live cells using an endosomolytic dimer of cell-penetrating peptide TAT.... Agent: The Texas A&m University System

20150099691 - Fpr1 antagonist derivatives and use thereof: each of RK and RT is selected from a group consisting of a hydrogen, a hydroxyl group, a C1-C4 alkyl-substituted hydroxyl group, a C1-C4 alkoxyl group, a carboxylic acid group, a C1-C4 alkyl nitrile-substituted, C1-C4 alkyl-substituted or C1-C4 alkoxyl-substituted amido group, a C1-C4 alkyl-substituted ester group and a benzoyl group... Agent: Chang Gung University

20150099692 - Anti-inflammatory peptides and composition comprising the same: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition... Agent: Gemvax As

20150099693 - Anti-inflammatory peptides and composition comprising the same: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of... Agent: Gemvax-as

20150099694 - Identification and susceptibility of microorganisms by species and strain: Devices, systems, and methods for strain-specific identification and assessment of susceptibility of microorganisms based on the response of sensors in a colorimetric sensor array to metabolic products of the microorganism.... Agent: Specific Technologies LLC

20150099695 - C1q/tnf-related protein-9 (ctrp9) and use in prevention and treatment of metabolic disorders: Compositions and methods for treatment of obesity and/or Type II diabetes and related metabolic disorders are provided wherein the methods and treatments comprise an effective amount of an isolated and/or purified C1q/TNF-related Protein-9 (CTRP9) or a functional portion thereof, and a pharmaceutically acceptable carrier. Methods of screening for molecules which... Agent:

20150099696 - Novel compounds for the treatment of dyslipidemia and related diseases: The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed to compounds suitable for... Agent: Cadila Healthcare Limited

20150099697 - Method for reversing recent-onset type 1 diabetes (t1d) by administering substance p (sp): Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the pharmaceutical composition reverses recent onset Type 1 Diabetes (T1D). Also described is a method for identifying an individual who will be responsive... Agent:

20150099698 - Combination peptide-nanoparticles and delivery systems incorporating same: Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms.... Agent:

20150099699 - Conjugates of insulin-like growth factor-1 and poly(ethylene glycol): A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or... Agent:

20150099700 - Methods for detecting progenitor cells and uses thereof: Diagnostic and therapeutic methods pertaining to diseases and disorders of the breast, uterus and ovary are encompassed herein. More particularly, diagnostic methods for early detection of progenitor cells of breast, uterine, and ovarian cancers are described herein. The identification of markers for these cancer predisposing progenitor cells, which co-express the... Agent:

20150099701 - Modified acidic fibroblast growth factors and composition thereof: The present invention provides acidic fibroblast growth factor (aFGF) composition, comprising: (i) aFGF of SEQ ID NO: 1, (ii) aFGF of SEQ ID NO: 1 having an N-terminal phosphogluconoylation, (iii) aFGF of SEQ ID NO: 1 having an N-terminal gluconoylation, (iv) aFGF of SEQ ID NO: 2 and (v) aFGF... Agent:

20150099702 - Use of rna interfearence, farnesoic acid and recombinant protein approach to induce gonad maturation in crustacean species: This invention is directed to the compositions and methods for inducing female gonad maturation in crustacean species such as shrimp, lobster or crab. In one embodiment, the composition for inducing gonad maturation comprises a dsRNA corresponding to the GIH DNA, recombinant protein of a gonad stimulatory hormone (GSH) and farnesoic... Agent:

20150099703 - Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent: The present invention refers to the use of certain sulfated glycosaminoglycans for treatment or prevention of postpartum haemorrhage. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with at least one uterotonic agent capable of promoting myometrial contractions of the uterus and thereby compress the vessels... Agent:

20150099704 - Peptide inhibitors of calcium oxalate monohydrate crystallization and uses thereof: In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid... Agent: Rensselaer Polytechnic Institute

20150099705 - Protoxin -ii variants and methods of use: The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.... Agent:

20150099706 - Treatment of ischemic stroke with dra1-mog-35-55: Methods and compositions used in treating ischemic stroke using a recombinant DRα-MOG-35-55 construct are disclosed. The disclosed methods involve administering a pharmaceutical composition comprising DRα-MOG-35-55 and a pharmaceutically acceptable carrier to a subject that has had or is at risk of developing ischemic stroke.... Agent: The United States Government As Represented By The Department Of Veterans Affairs

20150099707 - Modified pseudomonas exotoxin a: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of... Agent:

20150099708 - Wnt compositions and therapeutic uses of such compositions: The invention provides novel Wnt polypeptides that have improved production characteristics, solubility, systemic delivery, and tissue uptake, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and/or promoting... Agent:

20150099709 - Ghrelin receptor agonists for the treatment of achlorhydria: The present invention relates to a use of a compound having ghrelin receptor agonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for treatment of diseases including achlorhydria in which abnormal gastric acid secretion is involved. In addition, the present invention... Agent:

20150099710 - Feed additive, feed, and method for producing feed: Objects are to provide an additive for a feed which can improve growth performance and meat quality of livestock, and can improve palatability of the feed, a feed and a method for preparing the feed, and the objects can be solved by an additive for a feed which comprises at... Agent:

20150099712 - Method and compounds for inhibiting the mcm complex and their application in cancer treatment: A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM... Agent:

20150099711 - Method and system for modifying raw foods, and raw food product made thereby: A method for modifying a quality of a fruit includes cutting a live stem attached to a live fruit at a cut distance from the fruit, producing a cut end of the stem, contacting only the cut end of the stem with a solution comprising at least one mobile and... Agent: Nightshade, LLC

20150099713 - Method of treating constipation-predominant irritable bowel syndrome: Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufactiurc of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of... Agent: Cedars-sinai Medical Center

20150099714 - Synthesis of deuterated morpholine derivatives: s

20150099715 - Formulations of acadesine: This invention provides a buffered solution comprising acadesine, as well as compositions, formulations and kits containing said solution. The solution, compositions, formulation, and kits can be used to prevent morbidity/mortality in a patient or to treat an ischaemic condition, a condition regulated by adenosine, or a condition associated with reduced... Agent: Merck Sharp & Dohme Corp.

20150099792 - Antisense modulation of gcgr expression: Provided herein are methods, compounds, and compositions for reducing expression of GCGR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.... Agent: Isis Pharmaceuticals, Inc.

20150099796 - Compositions and methods for gene silencing: Compositions and methods for modulating the expression of a protein of interest are provided.... Agent:

20150099790 - Compositions and methods for modulating mitochondrial pyruvate carrier activity: Disclosed herein are methods and compositions for the diagnosis and treatment of conditions associated with aberrant pyruvate metabolism, and symptoms thereof, in a subject. Disclosed herein are methods of detecting an aberrant pyruvate metabolism-associated condition, and symptoms thereof, in a subject, by the expression level of MPC1 or MPC2. Disclosed... Agent:

20150099791 - Compositions and methods for modulating utrn expression: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of UTRN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of UTRN. Methods for modulating expression of UTRN using the single stranded oligonucleotides are also provided. Further aspects of the... Agent: The General Hospital Corporation D/b/a Massachussetts General Hospital

20150099794 - Gnaq targeted dsrna compositions and methods for inhibiting expression: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.... Agent:

20150099797 - Oligonucleotide compositions with enhanced efficiency: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide... Agent:

20150099793 - Rational design of microrna-sirna chimeras for multi-functional target suppression: The present disclosure encompasses methods for rational design of microRNA and small interfering RNA chimeras and compositions and methods of use thereof.... Agent:

20150099795 - Therapeutic agent for treating trypanosoma-associated disease, method for killing trypanosoma parasites, and use thereof: A therapeutic agent for treating a Trypanosoma-associated disease; a method of preventing infection by Trypanosoma parasites, or killing Trypanosoma parasites; and use thereof, the therapeutic agent and the method each using a mechanism different from a mechanism used in conventional technology. The therapeutic agent of the present invention for treating... Agent:

20150099799 - Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells: Methods for reducing recruitment, migration, or both recruitment and migration of polymorphonuclear cells to a site of inflammation in an organ of a human patient comprise administering locally to the organ or systemically to the patient in need thereof an isolated oligonucleotide selected from the group consisting of SEQ ID... Agent:

20150099798 - Variants of yeast ndi1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction: An isolated nucleic acid sequence encoding the yeast NDI1 protein of SEQ ID NO: 542 or a functional variant thereof is described. The nucleic acid sequence comprises at least 50 codons which are codon optimised compared with the sequence of yeast NDI1 gene of SEQ ID NO: 1.... Agent:

20150099716 - Maintenance of platelet inhibition during antiplatelet therapy: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who... Agent: The Medicines Company

20150099717 - Methods and kits for treating vaginal and vulvar vestibule mucosa disorders: A method of treating a vaginal or vulvar vestibule mucosa disorder involves administering a composition comprising a hyaluronic acid or a salt thereof to the vagina, vulvar or vulvar vestibule of an individual that has the disorder to treat the disorder. The method may be used to treat vaginal atrophy... Agent:

20150099718 - Heparin-based compositions and methods for the inhibition of metastasis: The invention provides the use in combination of a heparin containing composition that has anticoagulant activity when used alone, such as an unfractionated heparin or low molecular weight heparin, in combination with an inhibitor of the anticoagulation activity/effect or effect of heparin, for the inhibition of metastasis.... Agent:

20150099720 - Androgen receptor modulator compounds and methods: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such... Agent:

20150099719 - Cathepsin cysteine protease inhibitors: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.... Agent:

20150099721 - Treating cancer with hsp90 inhibitory compounds: A method for treating cancer with a mutation in ROS or RET, comprising identifying a subject with a cancer with a mutation in ROS or RET, and administering to the subject an effective amount of a compound according to formulae (I) OR (la) or a tautomer, or a pharmaceutically acceptable... Agent: Synta Pharmaceuticals Corp.

20150099722 - 6-oxopurine phosphoribosyltransferase inhibitors: The invention relates to compounds which are useful as inhibitors of 6-oxopurine phosphoribosyltransferases such as hypoxanthine-guanine-(xanthine) phosphoribosyltransferase (HG(X)PRT).... Agent:

20150099723 - Fatty acid acetylated salicylates and their uses: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.... Agent: Catabasis Pharmaceuticals, Inc.

20150099724 - Novel crystals and process of making 5-(-methyl)-2-methoxy-benzoic acid: The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.... Agent:

20150099726 - Dry powder inhaler: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 μg; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL... Agent: Teva Branded Pharmaceutical Products R&d, Inc.

20150099725 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine: The present patent application relates to a method of treating allergic rhinitis in a subject (preferably a human) by administering a combination of mometasone or its salt and olopatadine or its salt.... Agent:

20150099727 - Aminosteroids for the treatment of a ptp1b associated disease: This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.... Agent: Ohr Pharmaceutical Inc.

20150099732 - 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such... Agent:

20150099733 - Heteroarylcarboxylic acid ester derivative: e

20150099730 - Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer:

20150099734 - New diazaspirocycloalkane and azaspirocycloalkane:

20150099735 - Triazolopyridine compounds:

20150099731 - Use of parthenolide derivatives as antileukemic and cytotoxic agents:

20150099729 - Inhibitors of the renal outer medullary potassium channel:

20150099728 - Substituted phenylureas and phenylamides as vanilloid receptor ligands: Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.... Agent:

20150099736 - Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity: wherein R1, R2, R5 and R6 are independently selected from hydrogen, hydroxy, methyl, trifluoromethyl, hydroxymethyl, methoxy, trifluoromethoxy, methylamino and dimethylamino; R3, and R4 are independently selected from hydrogen, hydroxy, C1-C3 alkyl, fluoro-(C1-C3)-alkyl, hydroxy-(C1-C3)-alkyl, C1-C3 alkoxy, fluoro-(C1-C3)-alkoxy, hydroxy-(C1-C3)-alkoxy, —N(R11)—R12, -Alk-N(R11)—R12, —O-Alk-N(R11)—R12, —C(═O)OH, carboxy-(C1-C3)-alkyl, or —C(═O)—NH—R13; Alk is a straight or branched... Agent:

20150099737 - Pyrrolopyrimidine compounds as inhibitors of cdk4/6: The invention is directed to novel pyrrolopyrimidine compounds of formula (1) wherein R1, R2y, R4, R8-R11, A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are CDK4/6 inhibitors and could be useful in the treatment of diseases and disorders... Agent: Novartis Ag

20150099738 - Isoxazolines as inhibitors of fatty acid amide hydrolase: e

20150099739 - Modified release preparations containing oxcarbazepine and derivatives thereof: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.... Agent:

20150099740 - Treatment of central nervous system disorders: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising... Agent:

20150099741 - Diagnosing and treating patients having psychiatric disorders: Disclosed are methods and kits for diagnosing, prognosing, and treating patients having psychiatric disorders. The methods may include assessing whether a patient has a treatment resistant psychiatric disorder or assessing whether the patient is likely to develop a treatment resistant psychiatric disorder. The methods may include detecting genetic markers such... Agent: Northwestern University

20150099742 - Phantom phenomena treatment: The present invention relates to a substance for the treatment of the phantom phenomena of tinnitus and/or phantom pain, a method for the diagnosis and for the treatment of these phantom phenomena.... Agent: Otolanum Ag

20150099744 - Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors: The invention relates to combinations comprising an HDAC inhibitor and a Her2 inhibitor for the treatrent of breast cancer in a subject in need thereof. The invention also relates to combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need... Agent: Acetylon Pharmaceuticals, Inc.

20150099743 - Novel n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as pkc kinase inhibitors: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular... Agent:

20150099745 - Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione: Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.... Agent:

20150099746 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Agent:

20150099747 - Methods and compositions for detecting mutation in the human ezh2 gene: The invention comprises reagents and methods for detecting cancer-associated mutations in the human EZH2 gene. Further, a method of detecting the mutations and a method of treatment are disclosed.... Agent:

20150099749 - Hiv inhibiting 5-amido substituted pyrimidines: e

20150099748 - Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases: Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).... Agent:

20150099750 - Metalloenzyme inhibitor compounds: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.... Agent:

20150099751 - In situ gel loaded with phosphodiesterase type v inhibitors nanoemulsion: The in situ gel loaded with phosphodiesterase Type V (PDE5) inhibitors nanoemulsion was prepared using an innovative approach to reformulate the PDE5 inhibitors in a nanoemulsion, and then loading the nanoemulsion into an in situ gel base. These preparations are administered by intramuscular injection in order to give a depot... Agent: King Abdulaziz University

20150099752 - Pyrrolotriazinone derivatives as pi3k inhibitors: New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).... Agent: Almirall, Sa

20150099753 - Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine: The present invention provides individual crystalline polymorphs of 7-(tert-Butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine designated Form 5. The Form 5 polymorph disclosed herein is characterized according to one or more of (a) powder X-ray diffraction data (“XRPD”); (b) differential scanning calorimetry (“DSC”); (c) FT-Raman spectroscopy; (d) FT-IR spectroscopy; and (e) thermogravimetric analysis (TGA).... Agent:

20150099754 - Treatment of cancer characterized by gene mutations: Provided herein are methods for treating and/or preventing a cancer in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer characterized by particular gene mutation(s) or variant(s) relative to the genes of a biological wild-type sample.... Agent:

20150099755 - Novel fluoroergoline analogs: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors... Agent:

20150099756 - Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.... Agent:

20150099757 - Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders: e

20150099758 - Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof: The present application is related to compounds represented by Formula I, which are novel positive allosteric modulators of al nAChRs. The application also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on al nAChRs in a mammal by administering an effective amount of a compound... Agent: Anvyl LLC

20150099759 - Potent anticancer activity via dual compound activation: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods the use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations... Agent: Vanquish Oncology, Inc.

20150099760 - Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.... Agent: Novartis Ag

20150099761 - Modulators of fatty acid amide hydrolase: 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy... Agent: Janssen Pharmaceutica Nv

20150099762 - Compounds as rearranged during transfection (ret) inhibitors: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases... Agent:

20150099763 - Itraconazole compositions and dosage forms, and methods of using the same: The disclosure relates to, among other things, pharmaceutical compositions, such as solid oral dosage forms, comprising itraconazole, methods of making the compositions, and methods of using the same for treating disorders including, but not limited to, fungal infections.... Agent:

20150099764 - Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases: e

20150099765 - Compounds and compositions for cognition-enhancement, methods of making, and methods of treating: Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.... Agent:

20150099766 - Novel halogen-substituted compounds: in which the radicals A1, A2, A3, A4, Lm, Q, R1, T and U have the meaning given in the description and to the use of the compounds for controlling animal pests. In addition, the invention relates to processes and intermediates for the preparation of the compounds according to formula... Agent:

20150099767 - Sustained delivery formulations of risperidone compounds: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and... Agent:

20150099768 - Novel pharmaceutical formulations: There is provided inter alia a dry powder pharmaceutical formulation for inhalation comprising: (i) 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof and solvates thereof in particulate form as active ingredient; (ii) particulate lactose as carrier; and (iii) a particulate stabilizing agent... Agent:

20150099769 - Pyrrolo[3,2-d]pyrimidin-4-one derivatives and their use in therapy: wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis... Agent:

20150099770 - Carboxylic acid compounds: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one... Agent:

20150099771 - Pyridine cgrp receptor antagonists: The present invention is directed to pyridine derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions... Agent: Merck Sharp & Dohme Corp.

20150099772 - Substituted berbines and their synthesis: The present invention provides substituted berbines, processes for the synthesis of substituted berbine compounds, as well as intermediates used in the synthesis of substituted berbine compounds. Also provided are methods for using the substituted berbines to inhibit cancer cell growth.... Agent:

20150099773 - Process for the preparation of quaternary n-alkyl morphinan alkaloid salts: An improved process for the N-alkylation of tertiary morphinan alkaloid bases to form the corresponding quaternary morphinan alkaloid derivatives.... Agent:

20150099775 - Compositions and methods for treating cancers: The present invention relates to compositions and methods for treating of cancer. In some embodiments, the invention relates to the use of agents that can modulate a component in the CDX2-KLF4 signaling pathway to treat myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), adult T-cell leukaemia (ATLL),... Agent:

20150099774 - Pyrido [3,4-c] [1,9] phenanthroline and 11, 12 dihydropyrido [3,4-c] [1,9] phenanthroline derivatives and the use thereof, particularly for treating cancer: New phenanthroline derivatives as drug as well as methods for producing said compounds are provided.... Agent:

20150099776 - Beta-amyloid-directed multitarget compounds for the treatment of alzheimer's disease: The compounds of formula (I), or its pharmaceutically acceptable salts, or any stereoisomer or mixture thereof, wherein: R1 is a (C1-C2) alkyl radical; R2 and R3 are radicals independently selected from the group consisting of F, Cl and methyl R4 is H or OH; A is a birradical selected from... Agent: Universitat De Barcelona

20150099777 - Heterocyclic compound: e

20150099781 - Compounds and methods for treating mammalian gastrointestinal microbial infections: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The... Agent:

20150099780 - Deuterated cftr potentiators: s

20150099779 - Ror modulators and their uses: The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.... Agent:

20150099778 - Therapeutic agent for lower urinary tract disease: A method of treating a condition chosen from the group consisting of interstitial cystitis, cystitis, chronic nonbacterial prostatitis, chronic cystitis, prostatic hyperplasia, prostatitis, prostatism, bladder neck contracture, bladder inflammation, and overactive bladder by administering an amount of rebamipide or a pharmaceutically acceptable salt thereof to a human.... Agent: N.m.a. Co., Ltd.

20150099782 - Antagonists of prostaglandin ep3 receptor: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.... Agent: Pfizer Inc.

20150099783 - Use of ccr3-inhibitors: for use as a medicament for the treatment of diseases selected from dry age-related macular degeneration (dAMD), wet age-related macular degeneration (wAMD), retinopathy of prematurity (ROP), central retinal vein occlusion (CRVO), nasal polyposis, eosinophilic esophagitis, eosinophillic gastroenteritis (e.g. eosinophilic gastritis and eosinophilic ententeritis), hypereosinophilic syndrome and Churg Strauss syndrome.... Agent:

20150099784 - Piperazine, piperidine and tetrahydropyridine derivatives and their pharmaceutical use: Novel piperazine, piperidine and tetrahydropyridine derivatives comprising a dibenzofurane moiety are provided herein, as well as pharmaceutical compositions comprising same and therapeutic uses thereof.... Agent:

20150099785 - Stabilized efinaconazole compositions: The present invention provides compositions containing efinaconazole, butylated hydroxytoluene, a salt of ethylenediaminetetraacetic acid, and optional citric acid. The compositions exhibit stable color profiles and are useful in the treatment of fungal infections.... Agent:

20150099786 - Carboxamide compounds and their use as calpain inhibitors: in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH2—CH2, CH2—CH2—CH2, N(Ry#)—CH2, N(Ry#)—CH2—CH2 or CH═CH—CH═, each optionally having 1 or... Agent:

20150099787 - Non-flushing niacin analogues, and methods of use thereof: One aspect of the present invention relates to substituted pyridines and pharmaceutially acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically... Agent: Trustees Of Tufts College

20150099788 - Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia: The present invention provides methods of treating and preventing arrhythmia and other diseases or disorders, using ion channel modulating compounds, including vernakalant hydrochloride. The present invention further provides controlled release oral formulations and dosages of vernakalant hydrochloride, which are effective in preventing arrhythmia. Certain methods and formulations of the present... Agent:

20150099789 - Use of odiparcil in the treatment of a mucopolysaccharidosis: The present invention relates to a method of treatment of a mucopolysaccharidosis with 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-β-D-xylopyranoside.... Agent:

20150099800 - Novel lipase inhibitors, reporter substrates and uses thereof: The invention provides for novel lipase inhibitors, and compositions and devices comprising the same. The invention further provides for methods for treatment of disorders comprising administration of novel diacylglycerol lipase inhibitors, and compositions and devices comprising said inhibitors. In some embodiments, the disorders are pancreatitis, obesity, shock or pancreatic necrosis.... Agent:

20150099801 - Methods of preventing progression to type 2 diabetes mellitus: The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.... Agent:

20150099802 - Selective tumor treatment: A method for treating a tumor with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative, a method for suppressing the growth of a tumor cell with a decreased level... Agent: Sucampo Ag

20150099803 - Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies: The present invention is directed to methods for treatment of malignancies in companion animals employing dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol, as well as analogs and derivatives thereof, in addition to a method to improve the efficacy and/or reduce the side effects of the administration of a therapeutic agent selected from the... Agent:

20150099804 - Use of vanadium compounds to accelerate bone healing: This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone... Agent:

20150099805 - Hypotensive lipid-containing biodegradable intraocular implants and related methods: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.... Agent:

20150099806 - Compounds as l-cystine crystallization inhibitors and uses thereof: o

20150099807 - Preservative free bimatoprost solutions: The present invention is directed to preservative-free solutions of bimatoprost for lowering intraocular pressure and treatment of glaucoma.... Agent:

20150099808 - Amphiphilic copolymers and compositions containing such polymers: Amphiphilic copolymer, containing at least a hydrophilic chain segment (A) and a hydrophobic chain segment (B), wherein the hydrophilic chain segment (A) contains peptides and wherein the hydrophobic chain segment (B) contains acetal groups or orthoester groups. The hydrophilic chain segment (A) preferably contains glutamine/glutamic acid units or asparagines/aspartic acid... Agent:

20150099809 - Photolabile pro-fragrances: Many fragrances that provide a scent of freshness tend to be highly volatile and are therefore not very economical when used in typical applications such as washing or cleaning processes, so they have to be used in relatively large quantities to be able to produce adequate effects. The disclosed photolabile... Agent:

20150099810 - Photolabile pro-fragrances: Fragrances that provide a scent of freshness tend to be volatile and are therefore not very economical when used in typical applications such as washing or cleaning processes, so they have to be used in relatively large quantities to be able to produce adequate effects. The disclosed photolabile pro-fragrances provide... Agent:

20150099811 - Method and system to detect and diagnose alzheimer's disease: Various embodiments provide methods for the detection, the diagnosis, and/or the prediction of disease onset of Alzheimer's disease. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate, labeling the... Agent:

  
  
Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20150416: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.44828 seconds

PATENT INFO